344 unknown. 344 Phase 2, 87 Phase 3, 65 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 344 | Unknown 344 |
| Phase 3 | 87 | Unknown 87 |
| Phase 1 | 65 | Unknown 65 |
Follow Pneumonia: new trials by email Literature Review of Pneumonia trials Research Report on Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C), Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101) - COVID-19 | Phase 2 | Unknown | WestVac Biopharma Co., Ltd. | 3100 | 2024-12-30 | 2024-07-25 |
| Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia TP-122A - Pneumonia, Ventilator-Associated | Phase 1 / Phase 2 | Unknown | Technophage, SA | 15 | 2024-09-01 | 2024-04-17 |
| SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19) SHEN211 Tablets, Placebo for SHEN211 Tablets - COVID-19 | Phase 2 | Unknown | JKT Biopharma Co., Ltd. | 30 | 2024-04-01 | 2024-03-04 |
| NAC for Attenuation of COVID-19 Symptomatology N-acetylcysteine, Placebo - Covid19, COVID-19 Pneumonia | Phase 2 | Unknown | Cambridge Health Alliance | 200 | 2024-03-31 | 2023-08-07 |
| Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment Immunoglobulins - COVID-19 | Phase 2 | Unknown | Jaehoon Ko | 58 | 2024-03-18 | 2024-05-16 |
| Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure intravenous treatment with EVs, intravenous treatment with placebo solution - Severe Acute Respiratory Syndrome (SARS), Acute Respiratory Distress Syndrome (ARDS) | Phase 1 / Phase 2 | Unknown | D'Or Institute for Research and Education | 15 | 2024-02-01 | 2023-08-21 |
| Effect of High Dose Intravenous Vitamin C in Severe Pneumonia Active Ingredient, Placebo - Pneumonia | Phase 2 | Unknown | Clinical Research Centre, Malaysia | 484 | 2024-01-12 | 2024-06-20 |
| A Practical RCT of TCM in the Treatment of LCOVID and Analysis of Syndrome Types and Medication Characteristics. Traditional Chinese medicine treatment, Western medicine treatment - Long COVID | Phase 2 | Unknown | Chinese University of Hong Kong | 162 | 2023-12-01 | 2023-10-26 |
| Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19 50 μg Baiya SARS-CoV-2 Vax 2, Placebo - COVID-19 Vaccine, COVID-19 | Phase 2 | Unknown | Baiya Phytopharm Co., Ltd. | 75 | 2023-12-01 | 2023-11-15 |
| SLV213 Treatment in Ambulatory COVID-19 Patients SLV213, Placebo - Covid19 | Phase 2 | Unknown | Kenneth Krantz, MD, PhD | 81 | 2023-11-01 | 2023-04-12 |
| Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 autologous adipose-derived stem cells - COVID-19 | Phase 2 | Unknown | Celltex Therapeutics Corporation | 200 | 2023-09-01 | 2023-04-18 |
| To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M Prolectin-M - COVID-19, SARS CoV 2 Infection | Phase 2 | Unknown | Bioxytran Inc. | 40 | 2023-09-01 | 2023-09-28 |
| The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8) - Covid19, Novel Coronavirus Pneumonia | Phase 1 / Phase 2 | Unknown | AVEM HealthCare | 55 | 2023-09-01 | 2022-03-11 |
| Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients umbilical cord mesenchymal stem cell - Long COVID, Post-Acute COVID-19 Syndrome | Phase 1 / Phase 2 | Unknown | Changhai Hospital | 76 | 2023-09-01 | 2024-07-09 |
| tDCS in the Management of Post-COVID Disorders Transcranial Direct Current Stimulation (tDCS), Motor Training, Cognitive Training - Long COVID | Phase 2 | Unknown | Universidade Federal de Pernambuco | 48 | 2023-08-25 | 2024-04-24 |
| A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines SCTV01E-2, SCTV01E - COVID-19, SARS-CoV-2 Infection | Phase 2 | Unknown | Sinocelltech Ltd. | 600 | 2023-08-10 | 2023-07-06 |
| A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine COVID-19 mRNA Vaccine (ZSVG-02-O), COVID-19 Vaccine (Vero Cell) ,Inactivated - SARS-CoV-2 Infection | Phase 2 | Unknown | CNBG-Virogin Biotech (Shanghai) Ltd. | 980 | 2023-07-10 | 2023-11-08 |
| "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype. Baricitinib 4 MG - Hospital-acquired Pneumonia | Phase 2 / Phase 3 | Unknown | Nantes University Hospital | 450 | 2023-07-01 | 2023-06-22 |
| Beta-glucans for Hospitalised Patients With COVID-19 MC 3x3, Placebo - COVID-19 | Phase 2 | Unknown | Wohlstand Pharmaceutical | 60 | 2023-06-01 | 2022-12-13 |
| The Efficacy and Safety of a Chinese Herbal Medicine for Long COVID Associated Fatigue Shenlingcao Oral Liquid - Long COVID | Phase 2 | Unknown | Hong Kong Baptist University | 152 | 2023-05-30 | 2023-06-28 |
Showing 20 of 344. Sign in to see all of them.
COVID-19 (312) · Coronavirus Infections (32) · Respiratory Distress Syndrome (15) · Cytokine Release Syndrome (9) · Pneumonia, Viral (9) · Post-Acute COVID-19 Syndrome (9) · Severe Acute Respiratory Syndrome (9) · Pneumonia, Ventilator-Associated (8) · Inflammation (5) · Healthcare-Associated Pneumonia (4) · Pulmonary Fibrosis (4) · Acute Lung Injury (3) · Critical Illness (3) · Infections (3)
Respiratory Tract Diseases (343) · Lung Diseases (342) · Respiratory Tract Infections (342) · Infections (341) · Coronaviridae Infections (322) · Nidovirales Infections (322) · RNA Virus Infections (321) · Virus Diseases (320) · Pneumonia, Viral (312) · Coronavirus Infections (290) · Pathological Conditions, Signs and Symptoms (50) · Pathologic Processes (47) · Disease Attributes (29) · Respiration Disorders (18)
Hydroxychloroquine (21) · Standard of Care (15) · BNT162 Vaccine (13) · Saline Solution (11) · Ivermectin (9) · Azithromycin (8) · SCTV01C vaccine (8) · 2019-nCoV Vaccine mRNA-1273 (7) · Sodium Chloride (6) · COVID-19 Serotherapy (5) · COVID-19 Vaccines (5) · Injections (5) · Lopinavir (5) · Ritonavir (5) · favipiravir (5)
Sinocelltech Ltd. (10) · The University of Hong Kong (7) · Cairo University (6) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (5) · Tanta University (5) · D'Or Institute for Research and Education (4) · Kafrelsheikh University (4) · ANRS, Emerging Infectious Diseases (3) · Assistance Publique - Hôpitaux de Paris (3) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (3) · Livzon Pharmaceutical Group Inc. (3) · Makerere University (3) · National Vaccine and Serum Institute, China (3) · Shahid Beheshti University of Medical Sciences (3) · Shanghai Zerun Biotechnology Co.,Ltd (3)
China (43) · United States (25) · Brazil (17) · France (13) · Mexico (12) · Indonesia (11) · Russia (11) · Egypt (10) · Italy (9) · Pakistan (9) · United Arab Emirates (7) · Canada (6) · Colombia (6) · Hong Kong (6) · Iran (6)
Ivan FN Hung, MD FRCP (3) · Moneeb Ashraf, MBBS (3) · Muhammad Ashraf, PhD (3) · Sohaib Ashraf, MBBS (3) · Odile Launay (2) · Samba Sow (2) · Shoaib Ashraf, PhD (2) · Yang Wang, Ph.D. (2) · Abdol Hossein Shahverdi (1) · Abdoul Habib Beavogui (1) · Adriana Baltar, PhD (1) · Agung Putra, Assoc.Prof (1) · Ahmad Ameri, Prof. (1) · Ahmad Faried, Prof. MD (1)
PMID 34473343, PMID 31986264, PMID 32109013, PMID 32142651, PMID 25030060, PMID 29859173, PMID 31986257, PMID 32085846, PMID 32112977, PMID 32125455, PMID 32171076, PMID 32192578, PMID 32257537, PMID 36048877, PMID 36700518, PMID 37489818, PMID 10051178, PMID 10415784, PMID 10669330, PMID 10927736, PMID 10990547, PMID 11023960, PMID 11063978, PMID 11594901, PMID 11723286, PMID 11886437, PMID 12244081, PMID 12563677, PMID 12719004, PMID 12777656, PMID 12949224, PMID 1406879, PMID 14677403, PMID 14719037, PMID 15141377, PMID 15147306, PMID 15214887, PMID 15351385, PMID 15366588, PMID 15616839, PMID 15663512, PMID 15688692, PMID 15842354, PMID 15987799, PMID 16001071, PMID 16002441, PMID 16166518, PMID 16211552, PMID 16499032, PMID 16787239
2008 (1), 272201800011C-P00005-9999-1 (1)